Colgate-Palmolive (NYSE:CL) Position Increased by Candriam S.C.A.

Candriam S.C.A. increased its position in shares of Colgate-Palmolive (NYSE:CL) by 26.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 349,673 shares of the company’s stock after acquiring an additional 72,175 shares during the period. Candriam S.C.A.’s holdings in Colgate-Palmolive were worth $31,789,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of CL. FMR LLC raised its holdings in Colgate-Palmolive by 65.6% during the third quarter. FMR LLC now owns 6,749,275 shares of the company’s stock valued at $700,642,000 after buying an additional 2,674,807 shares in the last quarter. Barclays PLC grew its position in shares of Colgate-Palmolive by 38.7% in the third quarter. Barclays PLC now owns 7,644,189 shares of the company’s stock valued at $793,542,000 after purchasing an additional 2,132,747 shares during the last quarter. State Street Corp grew its position in Colgate-Palmolive by 3.8% during the third quarter. State Street Corp now owns 48,436,276 shares of the company’s stock worth $5,028,170,000 after buying an additional 1,784,411 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Colgate-Palmolive during the fourth quarter worth about $132,405,000. Finally, Nordea Investment Management AB grew its position in Colgate-Palmolive by 32.5% during the fourth quarter. Nordea Investment Management AB now owns 5,091,683 shares of the company’s stock worth $462,121,000 after buying an additional 1,247,731 shares in the last quarter. 80.41% of the stock is currently owned by institutional investors.

Colgate-Palmolive Price Performance

Shares of CL stock opened at $91.87 on Thursday. The firm has a market capitalization of $74.56 billion, a price-to-earnings ratio of 26.10, a price-to-earnings-growth ratio of 4.20 and a beta of 0.44. The company has a quick ratio of 0.58, a current ratio of 0.92 and a debt-to-equity ratio of 13.40. Colgate-Palmolive has a 12-month low of $85.32 and a 12-month high of $109.30. The firm has a fifty day moving average of $88.72 and a 200-day moving average of $95.27.

Colgate-Palmolive (NYSE:CL) last announced its earnings results on Friday, January 31st. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.01. Colgate-Palmolive had a net margin of 14.38% and a return on equity of 477.77%. During the same period last year, the firm posted $0.87 earnings per share. On average, equities research analysts forecast that Colgate-Palmolive will post 3.75 earnings per share for the current year.

Colgate-Palmolive Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, February 14th. Stockholders of record on Tuesday, January 21st were issued a $0.50 dividend. The ex-dividend date was Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.18%. Colgate-Palmolive’s payout ratio is 56.82%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CL. Royal Bank of Canada reissued a “sector perform” rating and set a $101.00 target price on shares of Colgate-Palmolive in a research report on Wednesday, January 29th. JPMorgan Chase & Co. decreased their price objective on Colgate-Palmolive from $103.00 to $97.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. TD Cowen decreased their price objective on Colgate-Palmolive from $110.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Piper Sandler decreased their price objective on Colgate-Palmolive from $121.00 to $112.00 and set an “overweight” rating on the stock in a report on Monday, January 6th. Finally, Raymond James reaffirmed an “outperform” rating and set a $105.00 price objective (down from $110.00) on shares of Colgate-Palmolive in a report on Monday, February 3rd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $101.61.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.